Investment Value Analysis of BeOne Medicines (ONC): Competitive Landscape and Valuation Outlook in the BTK Inhibitor Market

Based on the information I have collected, I now present to you an in-depth analysis report on the valuation outlook of BeOne Medicines amid the competitive landscape of the BTK inhibitor market.

---

BeOne Medicines Ltd. (NASDAQ: ONC) has established a leading position in the BTK inhibitor market with its core product BRUKINSA® (Zanubrutinib). The company currently has a market capitalization of USD 34.23 billion, a share price of USD 320.35, and an analyst consensus target price of USD 392.50, implying approximately 22.5% upside potential [0]. Against the backdrop of the BTK inhibitor market projected to expand at a 12% compound annual growth rate (CAGR), the company’s 2026 catalysts will be key drivers of valuation growth [1].

---

The global BTK inhibitor market is in a phase of rapid growth. According to market research data, the market size was approximately USD 9.4 billion in 2024 and is projected to reach USD 28.9 billion by 2034, representing a CAGR of 12% [1][2]. Another report forecasts the market will grow from USD 12.07 billion in 2025 to USD 23.99 billion in 2034, with a CAGR of 7.93% [3]. This growth is primarily driven by the following factors:

• Rising incidence of B-cell malignancies
• Growing demand for targeted BTK inhibitors with improved safety and efficacy profiles
• Progress in expanding new indications and combination therapy research
• Popularization of personalized treatment concepts

The BTK inhibitor market currently features a competitive landscape of two generations of products:

Product	Developing Company	Launch Year	Features
Ibrutinib	Pharmacyclics/Janssen	2013	First-generation BTK inhibitor, market pioneer; sales peaked in 2021 and have since declined
Acalabrutinib	AstraZeneca	2017	Second-generation BTK inhibitor with higher selectivity and reduced adverse reactions such as atrial fibrillation
Zanubrutinib (BRUKINSA®)	BeOne Medicines	2019	Second-generation BTK inhibitor demonstrating superior progression-free survival (PFS) and safety profiles
Pirtobrutinib	Eli Lilly	2023	Non-covalent BTK inhibitor that addresses drug resistance issues

According to research data presented at the 2025 IWCLL Conference, Zanubrutinib demonstrates significant clinical and economic advantages in the treatment of relapsed/refractory (R/R) CLL [4]:

• Progression-Free Survival (PFS) Advantage
  : The 24-month PFS rate of Zanubrutinib was 85.5%, significantly higher than Acalabrutinib’s 75.1%
• Number Needed to Treat (NNT) Analysis
  : An NNT of 10, meaning one disease progression or death event can be avoided for every 10 patients treated
• Cost-Effectiveness
  : Approximately USD 7,335 in direct treatment costs can be saved per patient

In the pivotal phase 3 ALPINE trial, Zanubrutinib demonstrated statistically significant and clinically meaningful PFS improvements compared to Ibrutinib [5], laying a solid foundation for its leading position in the BTK inhibitor market.

---

BRUKINSA (Zanubrutinib) is the primary engine of the company’s revenue growth, exhibiting strong sales momentum in Q3 2025 [6]:

Region	Q3 2025 Sales	Year-over-Year Growth Rate
U.S. Market	USD 739 million	+47%
European Market	USD 163 million	+68%
Chinese Market	Included in product revenue	Sustained growth

Company management explicitly stated that BRUKINSA has become the revenue leader in the global BTK inhibitor market, supported by its differentiated best-in-class clinical characteristics and long-term efficacy and safety data [6].

BeOne Medicines’ pipeline assets will reach several important milestones in 2026, and these catalysts are expected to significantly boost the company’s valuation:

As the most clinically advanced BTK degrader, BGB-16673 addresses BTK inhibitor resistance through a targeted protein degradation mechanism [7]:

• Efficacy Data
  (CaDAnCe-101 Phase 1 Study):
  • R/R CLL/SLL patients: Overall Response Rate (ORR) reached 84.8%, with the ORR in the 200mg recommended dose group as high as 93.8%
  • R/R WM patients: ORR was 84.4%, major response rate 75%, very good partial response (VGPR) 31.3%
  • The median number of prior treatment lines for patients was 4, with most having received BTK inhibitor and BCL2 inhibitor treatment
  • 12-month progression-free survival rate reached 77.4%
• Safety Profile
  : Well-tolerated, no tumor lysis syndrome (TLS) observed; grade 3 or higher adverse events were primarily neutropenia (24%), and no atrial fibrillation was reported

Fixed-duration combination therapy with BRUKINSA demonstrates significant efficacy [7]:

• R/R CLL/SLL
  : ORR reached 96%, complete response rate 52%, and 82% of patients achieved undetectable minimal residual disease (uMRD)
• R/R MCL
  : ORR reached 79%, complete response rate 66%, and 84% of responding patients remain in ongoing remission

Timeframe	Catalyst
First half of 2026	Potential pivotal phase 2 data readout of BGB-16673 in R/R CLL
2026	Global first approval and commercial launch of Sonrotoclax
2026	Initiation of pivotal phase 3 trial for BTK CDAC (BGB-16673)
2026	Results of head-to-head phase 3 trial vs. Ibrutinib

---

Based on the latest financial data [0][6]:

Metric	Q3 FY2025	Year-over-Year Change
Total Revenue	USD 1.41 billion	+41%
Product Revenue	USD 1.77 billion	Primarily driven by BRUKINSA
Earnings Per Share (EPS)	USD 1.09	Exceeded expectations by 51.39%
U.S. Market Revenue	USD 754 million	53.4% of total revenue
European Market Revenue	USD 167 million	11.8% of total revenue
Chinese Market Revenue	USD 440 million	31.1% of total revenue

The company remains in a loss-making state (TTM net profit margin -4.24%), which aligns with the business model of biopharmaceutical companies with high R&D investment. The company’s financial stance is categorized as “conservative,” reflected in a high depreciation/capital expenditure ratio. As R&D investments gradually mature, profitability prospects are expected to improve [8].

[0]:

• Market Capitalization: USD 34.23 billion
• Price-to-Sales (P/S) Ratio: 9.58x
• Price-to-Book (P/B) Ratio: 1.21x

[0]:

• Consensus Rating: Buy (100% of analysts give a Buy rating)
• Target Price Range: USD 383-420
• Median Target Price: USD 392.50
• Potential Upside: +22.5%

[9]:

• Current price is in a sideways consolidation phase
• Key technical levels: Support at USD 313.61, resistance at USD 325.13
• MACD indicator shows a bullish crossover, KDJ indicator signals a bullish trend
• Beta coefficient of 0.47, indicating low correlation with the broader market

---

Competition in the BTK inhibitor market is intensifying, with key risks including:

1. Sustained Competition from Acalabrutinib
   : AstraZeneca continues to expand its market share with strong commercial capabilities
2. Eli Lilly’s Pirtobrutinib
   : As a non-covalent BTK inhibitor, it addresses partial drug resistance issues
3. Next-Generation BTK Degraders
   : Other pharmaceutical companies are also developing degraders with similar mechanisms
4. Generic Drug Threat
   : Ibrutinib may face generic competition after patent expiration

• Clinical trial results falling short of expectations
• Delays in regulatory approval or requirements for additional data
• Emergence of safety signals that may impact product prospects

• Sustained pressure on drug pricing
• Changes in medical insurance reimbursement policies may impact revenue
• Global market access challenges

---

BeOne Medicines has multiple drivers of valuation growth in 2026 and beyond:

1. Sustained Growth of Core Product
   : BRUKINSA maintains strong growth momentum in the U.S. and European markets, with U.S. sales growing 47% year-over-year in Q3 2025, and is expected to continue expanding its market share

2. Intensive Catalyst Releases in 2026
   :
   • Key data readout of BGB-16673 (first half of 2026)
   • Global first approval of Sonrotoclax
   • Initiation of pivotal phase 3 trial for BTK CDAC

3. Market Expansion
   : The BTK inhibitor market is projected to grow at a 12% CAGR, and the company, as a market leader, will fully benefit from this growth

4. Pipeline Diversification
   : In addition to the BTK field, the company has a presence in the solid tumor area (e.g., Ziihera), reducing reliance on a single product

Considering the company’s competitive advantages, 2026 catalysts, and risk factors, we believe BeOne Medicines’ leading position can support its valuation growth in 2026 and beyond, but the following key points require attention:

Evaluation Dimension	Rating	Explanation
Competitive Position	Strong	BRUKINSA has established a market leading position, supported by clinical data demonstrating differentiated advantages
Pipeline Potential	Strong	BGB-16673 and Sonrotoclax have best-in-class potential
2026 Catalysts	Abundant	Multiple key data readouts and regulatory milestones
Valuation Reasonableness	Neutral Bullish	A P/S ratio of 9.58x is attractive for a high-growth biopharmaceutical company
Risk Factors	Exist	Intensifying market competition, clinical trial risks

Investors should focus on the following indicators:

• Quarterly sales growth trend of BRUKINSA
• Updates on BGB-16673 clinical trial data
• Regulatory approval progress of Sonrotoclax
• Results of the head-to-head trial vs. Ibrutinib
• Market share change trends

---

Against the backdrop of intensifying competition in the BTK inhibitor market, BeOne Medicines has established a leading market position with BRUKINSA’s superior efficacy and safety data demonstrated in key clinical trials. The company’s 2026 catalysts—including key data from BTK degrader BGB-16673 and the commercial launch of BCL2 inhibitor Sonrotoclax—are expected to be important drivers of valuation growth.

Despite competitive pressure from rivals such as Acalabrutinib and Pirtobrutinib, as well as uncertainties in clinical trials and regulatory approval, the company’s diversified pipeline, strong sales growth momentum, and widespread Buy ratings from analysts provide support for its valuation. The current P/S ratio of 9.58x has reasonable valuation premium justification for a high-growth biopharmaceutical company with abundant catalysts.

It is recommended that investors pay attention to the BGB-16673 data readout in the first half of 2026 and the regulatory approval progress of Sonrotoclax, as these catalysts will be key nodes to verify the company’s long-term valuation potential.

---

[0] Jinling API - BeOne Medicines Company Overview, Real-Time Quotes, and DCF Valuation Data
[1] GM Insights - BTK Inhibitor Market Analysis, Statistics & Forecast, 2034 (https://www.gminsights.com/industry-analysis/btk-inhibitor-market)
[2] Research and Markets - BTK Inhibitor Market Growth Projection (https://www.researchandmarkets.com/content-images/2292/2292881/1/btk-inhibitor-market.png)
[3] Market Growth Reports - Bruton Tyrosine Kinase (BTK) Inhibitors Market Report (https://www.marketgrowthreports.com/market-reports/bruton-tyrosine-kinase-btk-inhibitors-market-116841)
[4] IWCLL 2025 - Number Needed to Treat Analyses of Zanubrutinib vs Acalabrutinib in R/R CLL (https://www.iwcll.org/work/biennial-meetings/iwcll-xxi-biennial-meeting-2025/2025-poster-gallery/number-needed-to-treat-analyses-of-zanubrutinib-vs-acalabrutinib-in-relapsed-refractory-chronic-lymphocytic-leukemia/)
[5] Blood Journal - Updated efficacy and safety results of BTK degrader BGB-16673 (https://ashpublications.org/blood/article/146/Supplement 1/3584/551386/Updated-efficacy-and-safety-results-of-the-Bruton)
[6] BeOne Medicines Q3 2025 Financial Results (https://www.biospace.com/press-releases/beone-medicines-announces-third-quarter-2025-financial-results-and-business-updates)
[7] BeOne Medicines EHA 2025 Data Showcase (https://www.biospace.com/press-releases/beone-medicines-showcases-breakthrough-data-in-cll-and-mcl-at-eha-2025)
[8] Jinling API - BeOne Medicines Financial Analysis Report
[9] Jinling API - BeOne Medicines Technical Analysis Report